Investors Compete To Lead Pfizer Derivative Suit

Law360, New York (October 9, 2009, 1:32 PM EDT) -- Institutional investor Amalgamated Bank is competing with an individual shareholder over who will lead a consolidated derivative lawsuit alleging that Pfizer Inc.'s executives harmed the company by promoting prescription drugs for unapproved, off-label uses.

At least eight derivative complaints have been filed in the U.S. District Court for the Southern District of New York since Pfizer agreed last month to pay a record $2.3 billion in civil and criminal fines.

On Thursday, individual shareholder Henrietta Klein lodged a motion requesting that the current cases and all...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.